Last reviewed · How we verify
Time delay treatment of botulinum toxin
Time delay treatment of botulinum toxin is a Small molecule drug developed by University Hospital, Clermont-Ferrand. It is currently in Phase 3 development.
Botulinum toxin works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.
At a glance
| Generic name | Time delay treatment of botulinum toxin |
|---|---|
| Sponsor | University Hospital, Clermont-Ferrand |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
This results in temporary muscle paralysis, which can be used to treat a variety of conditions, including muscle spasms and excessive sweating. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of the SNARE complex, which is necessary for the release of acetylcholine from nerve terminals.
Approved indications
Common side effects
Key clinical trials
- Evaluation of Tibial Nerve Selective Neurotomy Compared to Botulinum Toxin Injections for Spastic Foot Treatment in Post-stroke Patients According to a Goal-centered Approach (NA)
- HEMITOX : Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Time delay treatment of botulinum toxin CI brief — competitive landscape report
- Time delay treatment of botulinum toxin updates RSS · CI watch RSS
- University Hospital, Clermont-Ferrand portfolio CI